Tiapamil
chemical compound
Tiapamil (INN; also known as dimeditiapramine) is a calcium antagonist or calcium channel blocker. It is an experimental drug that has never been marketed.
Tiapamil has been described as an antianginal agent. It exhibits properties of anti-arrhythmic medications. These are medications that are used to treat unusually fast or irregular heartbeats. Examples of arrhytmthic conditions include atrial fibrillation, atrial flutter, and super-ventricular tachycardia. Upon research, the drug shows promising effects on treatment of these condition. Research seeks to create a treatment with tiapamil in order to mitigate the side effects of the more commonly prescribed calcium antagonist and anti-hypertensive verapamil. The two drugs have similar properties; however, tiapamil appears to treat arrhythmic conditions without many of the hypotensive, negative inotropic, and negative chronotropic side effects. Tiapamil is a calcium channel blocker that acts on the slow calcium channels.
“Tiapamil” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Tiapamil, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Tiapamil” is worth following because a concise public description often conceals a longer documentary argument. Here, Tiapamil, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Aug 21, 2026. The linked authority identifier is Q5277228. None of the 0 selected statements returned an explicit reference.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Tiapamil”, its source revision and the description used here.
- Expand the search: follow Tiapamil primary sources, Tiapamil archive and Tiapamil research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Tiapamil”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Tiapamil” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.